Pulmonx (LUNG) Net Income towards Common Stockholders (2019 - 2025)
Pulmonx (LUNG) reported Net Income towards Common Stockholders of -$14.0 million for Q3 2025, up 1.38% year-over-year from -$13.8 million in Q3 2024, and up 8.15% on a QoQ basis from -$15.2 million in Q2 2025.
Pulmonx (LUNG) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$14.0 million in Q3 2025.
- Quarterly Net Income towards Common Stockholders rose 1.38% year-over-year to -$14.0 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$43.6 million (up 22.78% YoY) and the FY2024 annual result came in at -$56.4 million, up 7.31% from the prior year.
- Net Income towards Common Stockholders advanced to -$14.0 million in Q3 2025 per LUNG's latest filing, from -$15.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$10.2 million in Q3 2021 and bottomed at -$16.2 million in Q2 2023.
- The 5-year median for Net Income towards Common Stockholders is -$14.2 million (2022), against an average of -$14.1 million.
- The widest annual swing landed in 2021, when Net Income towards Common Stockholders plunged 163.76%; it then advanced 13.31% in 2024.
- Tracing LUNG's Net Income towards Common Stockholders over 5 years: stood at -$13.0 million in 2021, then dropped by 9.95% to -$14.3 million in 2022, then increased by 2.65% to -$13.9 million in 2023, then gained by 5.29% to -$13.2 million in 2024, then fell by 5.94% to -$14.0 million in 2025.
- Per Business Quant, the three latest LUNG Net Income towards Common Stockholders figures stand at -$14.0 million (Q3 2025), -$15.2 million (Q2 2025), and -$14.4 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 199.50 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Pulmonx | 67.30 Mn | -2.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -13.96 Mn |
| Jun 30, 2025 | -15.20 Mn |
| Mar 31, 2025 | -14.41 Mn |
| Dec 31, 2024 | -13.18 Mn |
| Sep 30, 2024 | -14.15 Mn |
| Jun 30, 2024 | -15.34 Mn |
| Mar 31, 2024 | -13.75 Mn |
| Dec 31, 2023 | -13.91 Mn |
| Sep 30, 2023 | -14.94 Mn |
| Jun 30, 2023 | -16.20 Mn |
| Mar 31, 2023 | -15.86 Mn |
| Dec 31, 2022 | -14.29 Mn |
| Sep 30, 2022 | -14.17 Mn |
| Jun 30, 2022 | -14.64 Mn |
| Mar 31, 2022 | -15.86 Mn |
| Dec 31, 2021 | -13.00 Mn |
| Sep 30, 2021 | -10.18 Mn |
| Jun 30, 2021 | -12.96 Mn |
| Mar 31, 2021 | -12.51 Mn |
| Dec 31, 2020 | -9.29 Mn |
| Sep 30, 2020 | -3.86 Mn |
| Jun 30, 2020 | -11.96 Mn |
| Mar 31, 2020 | -7.16 Mn |
| Dec 31, 2019 | -4.67 Mn |
| Sep 30, 2019 | -4.34 Mn |